Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
RPRX · Nasdaq · United States · Pharmaceutical Preparations
In shortRoyalty Pharma plc is profitable, generates cash and carries moderate debt, with revenue growing (+5.1% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 65.6% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 32.4% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 7.7% | 38/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 8.4% | 56/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.40× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.92× | 60/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.32× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 5.07× | 34/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.25 | 30/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 104.7% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 3.23× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 5.2% | 92/100 |
| Operating margin volatility | 21.9% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.1% | 28/100 |
|---|---|---|
| EPS growth, 3-year average | 161.1% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
3 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2,289 | 2,237 | 2,355 | 2,264 | 2,378 |
| Research & development | 200 | 177 | 52 | 2 | 452 |
| Operating income | 1,431 | 307 | 1,492 | 1,292 | 1,560 |
| Interest expense | 166 | 188 | 187 | 226 | 308 |
| Pre-tax income | 1,241 | 230 | 1,700 | 1,331 | 1,324 |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | 620 | 43 | 1,135 | 859 | 771 |
| Diluted EPS | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| Diluted shares (millions) | 415 | 438 | 603 | 594 | 564 |
3 older years available with the 10-year history. Essential plan, from €8.25/month →
2.25 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026